Although patients with a clinical diagnosis of cardiac failure comprised <10% of our trial population, more granular echocardiographic data might have provided more insights as to why ∼40% of SPACE patients had NT-proBNP concentrations approaching or exceeding those indicative of structural heart disease or cardiac failure.42 The gene discussed is NPPB; the disease is heart failure.